1189975-18-5

Usage

Uses

Used in Pharmaceutical and Organic Synthesis:
[4-(4-Aminophenoxy)(2-pyridyl)]-N-(methyl-d3)carboxamide is used as a reactive intermediate for the synthesis of pharmaceuticals and organic compounds due to the favorable reactivity of its aminophenoxy and pyridyl moieties. These functional groups can participate in various chemical reactions, facilitating the creation of new molecules with potential therapeutic or industrial applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, [4-(4-Aminophenoxy)(2-pyridyl)]-N-(methyl-d3)carboxamide is used as a building block for the development of new drugs. Its unique structure allows for the design of molecules with specific biological activities, potentially leading to the discovery of novel therapeutic agents.
Used in Drug Discovery:
[4-(4-Aminophenoxy)(2-pyridyl)]-N-(methyl-d3)carboxamide is utilized as a starting material in drug discovery processes. Its diverse functional groups enable the exploration of various chemical modifications, which can enhance the compound's pharmacological properties and improve its potential as a drug candidate.
Used in Biochemical Research:
In biochemical research, [4-(4-Aminophenoxy)(2-pyridyl)]-N-(methyl-d3)carboxamide is employed as a tool for isotopic labeling. The incorporation of deuterium atoms in the N-(methyl-d3)carboxamide group allows researchers to study metabolic pathways and enzyme mechanisms, providing valuable insights into biological processes.
Used in Chemical Synthesis:
[4-(4-Aminophenoxy)(2-pyridyl)]-N-(methyl-d3)carboxamide is used as a versatile reagent in chemical synthesis. Its unique structure and functional groups make it a valuable component in the preparation of a wide range of organic compounds, contributing to the advancement of organic chemistry.

Upstream product

• 5470-22-4 4-chloropicolinic acid 
• 24484-93-3 4-Chloro-pyridine-2-carboxylic acid methyl ester 
• 98-98-6 2-Picolinic acid 
• 53750-66-6 4-chloro-pyridine-2-carbonyl chloride 
• 59-67-6 nicotinic acid 
• 1189858-48-7 4-chloropyridinyl-2-(N-1',1',1'-trideuteromethylcarboxamide) 
• 123-30-8 4-amino-phenol 

Downstream Products

• 1130115-44-4 N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl-d₃)aminoformyl)-4-pyridyloxy)phenyl)urea 
• 1333386-17-6 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxyl)-2-(N-1’,1’,1’-trideuteromethyl)pyridine amide p-toluenesulfonate 

Relevant academic research and scientific papers

Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities

Deuterium substitution has been widely known that can improve the pharmacokinetic profiles due to isotope effect. Herein, a series of deuterated sorafenib derivatives have been synthesized and characterized by 1H NMR, 13C NMR and MS. Their antitumor activities were evaluated in vitro against human hepatoma cell line HepG2 and human cervical carcinoma cell line HeLa. The LogP values were detected by high-performance liquid chromatography. Subsequently, the metabolic stability and pharmacokinetics study were assessed in vitro and in vivo.

Preparation deuterated diphenylurea (by machine translation)

The invention relates to a method for preparing deuterated diphenyl urea. Specifically, the invention provides an intermediate N-(1, 1, 1-3 deuterated methyl) benzo succinimide which can be used for preparing a deuterated diphenyl urea compound and an application of the intermediate in the preparation of the deuterated diphenyl urea compound. The method can be used for conveniently preparing the intermediate with the high purity and various deuterated diphenyl urea compounds in high efficiency.

Deuterated bisarylurea compound and preparation method thereof, and application of compound in preparation of antitumor drug

The invention provides a deuterated bisarylurea compound and a preparation method thereof, and application of the compound in preparation of an antitumor drug. The compound has a structure as shown in a general formula (I). The preparation method comprises the following steps: with methyl 4-chloropyridine-2-formate as a raw material, sucjecting methyl 4-chloropyridine-2-formate and methylamine or deuterated methylamine to a substitution reaction; then subjecting a product obtained in the previous step to condensation with p-aminophenol or deuterated p-aminophenol; and reacting a product obtained in the previous step with 4-chloro-3-(trifluoromethyl)phenyl isocyanate or deuterated 4-chloro-3-(trifluoromethyl)phenyl isocyanate so as to prepare the deuterated bisarylurea compound. Experiment results show that the deuterated bisarylurea compound provided by the invention has tumor treatment effect. The invention also provides application of the compound to research and development of the antitumor drug.

POLYMORPHS OF DEUTERATED OMEGA-DIPHENYLUREA OR SALTS THEREOF

The invention relates to polymorphs of deuterated omega-diphenylurea or salts thereof. In particular, the invention provides polymorphs of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl)-ureido]-phenoxy}-2-(N-1′,1′,1′-trideutero-methyl)picolinamide or its sa

PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA

A fluoro-substituted deuterated diphenylurea compound, especially 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-2-(N-(methyl-d3))picolinamide, preparing method and use for treating or preventing tumor and relative diseases thereof.

METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA

Methods and processes for preparation and production of deuterated ω-diphenylurea are disclosed. Especially, a kind of deuterated ω-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trifluoromethyl)phenye-N′-(4-(2-(N-d3-methylcarbamoyl)-4-pridinyloxy)phenyl)urea are disclosed. The said deuterated diphenylurea compounds can be used for treating or preventing tumors and relative diseases.

PREPARATION METHODS OF METHYL-D3-AMINE AND SALTS THEREOF

Preparation methods of methyl-d3-amine and salts thereof are provided, which contain the following steps: (i) nitromethane is subjected to react with deuterium oxide in the present of bases and phase-transfer catalysts to form nitromethane-d3, which is subsequently subjected to reduction in an inert solvent to form methyl-d3-amine, and optionally, methyl-d3-amine reacts subsequently with acids to form salts of methyl-d3-amine; or (ii) N-(1,1,1-trideuteriomethyl)phthalimide is subjected to react with acids to form salts of methyl-d3-amine. The present methods are easy, high efficient, and low cost.

METHOD FOR PREPARING DEUTERATED DIPHENYLUREA

Disclosed are an intermediate compound of N-(1,1,1-trideuterated methyl)phthalimide, and its use in the preparation of deuterated diphenylurea derivative.

METHOD FOR PREPARING DEUTERATED DIPHENYLUREA

Disclosed are an intermediate compound of N-(1,1,1-trideuterated methyl)phthalimide, and its use in the preparation of deuterated diphenylurea derivative.

DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS

This invention relates to deuterated ω-diphenylurea and derivatives and pharmaceutical acceptable salts thereof. And the pharmaceutical compositions comprising the pharmaceutically acceptable carrier and the deuterium-substituted ω-diphenylurea and derivatives and pharmaceutical acceptable salts thereof are also provided. The deuterium-substituted diphenylurea can be used in treatment or prevention of cancer and other related diseases.